ABSTRACT
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the general population [1] as well as in patients with chronic kidney disease (CKD) [2, 3] . Beyond traditional cardiovascular risk factors like hypertension, diabetes and dyslipidemia, which underestimate the risk in CKD patients [4, 5] , CVD in CKD is also associated with hyperphosphatemia [6] .
There is strong observational evidence showing that higher fasting serum phosphate levels are associated with a greater risk for cardiovascular disease in patients with CKD as well as in the general population [7] [8] [9] [10] . Thus, in subjects with normal renal function, serum phosphate was positively associated with carotid intima-media thickness (cIMT) [11] and even with mortality [12] independently of traditional cardiovascular risk factors. The main mechanism involved in the pathophysiology of phosphate-induced cardiovascular risk is vascular calcification. However, high phosphate levels have been also associated with endothelial dysfunction [13, 14] which can increase the risk for atherosclerosis and hypertension [15, 16] . Thus phosphate may promote plaque development or rupture independently of its classical effects in vascular calcification [17] .
The new guidelines on the assessment of cardiovascular risk [18] reiterate a key concept that has been known for decades, namely that men are at higher risk for cardiovascular disease than women independently of other known risk factors. As it has been demonstrated with traditional cardiovascular risk factors, the association of serum phosphorus with subclinical and clinical CVD in the general population could be different in men than in women [19] . For instance, in the ARIC study, a large community-based observational study of middle aged adults predominantly without CKD, high serum phosphorus levels were associated with cIMT and CV events only in men.
On the basis of sex differences of phosphorus with subclinical and clinical CVD in the general population, we hypothesized that phosphorus levels would also be associated with greater asymptomatic atherosclerosis burden in CKD, and that this association would be different in men than in women. The results of this study show for the first time, that the effect of phosphate levels in the atherosclerosis burden of CKD patients differs according to sex.
MATERIALS AND METHODS

Patients
Study population included 1687 chronic kidney disease patients not in dialysis from the Spanish Multicenter Study NEFRONA. The Nefrona study is an observational, prospective, multicenter 4-year study aimed to assess the predictive value of non-invasive imaging techniques and biomarkers on CV events and mortality in a large cohort of Spanish patients with CKD. This is an ancillary study of the NEFRONA study, which has been extensively described [20, 21] .
Briefly, patients were sequentially enrolled from 81 different hospitals throughout Spain, referred by their nephrologist between October 2010 and June 2012. The study was approved by each local ethics committee and subjects were included after providing informed consent. The tests were sequentially carried out by three trained itinerant teams composed each one of one technician and one nurse. Patients were eligible for inclusion if they had CKD (glomerular filtration rate (GFR) < 60 ml/min per 1.73 m²) stages 3 to 5 not in dialysis and age between 18 and 74. Candidates were asymptomatic and without previous cardiovascular events at the time of recruitment.
CKD stage was based on estimated GFR in ml/min per 1.73 m 2 , as determined by the four-variable Modification of Diet in Renal Disease (MDRD4) Study equation [22] and was categorized as stage 3 (GFR ≤60 ml/min and >30 ml/min per 1,73 m 2 ) and stage 4/5 (GFR ≤30 ml/min per 1.73 m 2 without renal replacement therapy).
Absence of cardiovascular disease was defined as absence of a history of coronary artery disease (myocardial infarction, coronary artery bypass graft surgery, coronary stent, or presence of stenosis on coronary angiography), heart failure (ejection fraction <45% or the presence of moderate or severe diastolic dysfunction by echocardiography) or peripheral arterial disease (claudication or vascular bypass surgery) or cerebrovascular disease (stroke).
Phosphate levels were categorized in ranges of clinical significance as follows: 0-3.5 mg/dl, 3.51-5 mg/dl and 5.1-10 mg/dl. Age was also categorized as follows: 18-45; 46-55; 56-65; >65 years. Smoking background included current as well as past history. Diabetes was defined as fasting glucose level ≥ 126 mg/dl or use of hypoglycaemic medication. Blood pressure was measured before the vascular exploration 3 times in the seated position with a five minutes rest period between measurements with a validated semi-automatic oscillometer (Omron HEM-705CP). The average of the second and third readings was recorded.
Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥90 mmHg, or use of medications prescribed for hypertension.
Use of medications was based on clinical staff entry of prescriptions and confirmed with the patients.
Body mass index (BMI) was calculated using the following equation: weight (kg)/height (m 2 ). Biochemical blood test was obtained from fasting analysis in recent clinical records (within 3 months of the vascular ultrasound).
Imaging methods
All the participants in the study underwent the same carotid and femoral ultrasound protocol as previously described [23] . B-mode ultrasound imaging of the right and left carotid arteries was performed using a General Electric instrument (Vivid BT09 model) equipped with 6-13 MHz broadband linear array transducers. This examination was used to measure cIMT to identify the presence of carotid plaques according to the Mannheim consensus [24] . Thus, cIMT equal or above 1.5 mm was considered as an atheroma plaque. The far wall of the common carotid, bulb and internal carotid arteries were scanned.
We measured cIMT using the semiautomated U.S. Food and Drug Administration-approved software, EchoPAC Dimension (General Electric) based on detection of the echo structures. The ultrasounds were performed by the same itinerant team and were analysed by a unique reader in a blinded fashion. Femoral ultrasound was performed with the aim to identify atheromatous plaques in the common and superficial femoral arteries.
Statistical analysis
Fisher, Spearman, Mann-Whitney and Kruskal Wallis tests were conveniently used to evaluate the effect of baseline characteristics on phosphate levels. The use of these non-parametric tests was due to the lack of normality for most variables (not shown) but also for the reduced sample size. In addition, a multivariate linear model was fitted to assess the joint effect of the clinical variables on phosphate levels. To study the risk factors associated to the presence of plaque a colour grid was used to represent the percentage of plaques as a function of age and phosphate levels. A multivariate logistic regression model was performed to globally assess the effects of all clinical variables, including phosphate levels, on the presence/absence of plaques. A stepwise procedure based on Akaike's Information Criterion was used to determine the linear and logistic multivariate models. All the analyses were performed using R statistical package, setting the threshold for significance at 5% (=0.05)
RESULTS
A total of 1687 CKD patients were considered for the analysis (906 stage 3, 594 stage 4 and 187 stage 5). Mean age at study entry was 59.9 ±11.8 years;
62.8% were males; 54.6% were current or former smokers; 28.5% were diabetics; 91% had hypertension; 71.1% had dyslipidaemia.
The mean serum phosphate was significantly higher in women (3.88 ± 0.72 mg/dl) than in men (3.62 mg/dl ± 0.8 mg/dl) (p<0.00001). 21% of the patients were on phosphate binders. Table 1 depicts the association of the serum phosphate level, using the intervals 0-3.5, 3.51-5 and 5.1-10 mg/dl, with the clinical variables, separately for men and women. Men showed a higher proportion of cases in the lowest range of phosphate while most women had phosphate levels higher than 3.5 mg/dl. Among men, those with phosphate level higher than 3.5 mg/dl were significantly younger. Mean cholesterol, LDL and eGFR levels were significantly lower in men with a phosphate level higher than 5 mg/dl. Conversely systolic blood pressure was higher in this group of patients. The proportion of diabetics increased progressively in the three intervals considered. Among women, the proportion of smokers or former smokers was significantly lower for patients with phosphate levels between 3.51 and 5 mg/dl. Mean eGFR levels decreased progressively along the three intervals considered. Systolic blood pressure was also positively correlated with phosphate levels.
Factors associated with higher phosphate levels
The multivariate linear analysis to model serum phosphate levels (Table 2) showed a significant effect of sex, diabetes, hypertension, age, eGFR and PTH and, more interestingly, revealed that sex significantly interacted with age and also that eGFR interacted with hypertension, PTH and cholesterol. More particularly, the interaction of sex and age with respect to phosphate levels is illustrated in Figure 1 , showing that as age increased phosphate levels in men decreased (r=-0.19, p<0.00001) whereas in women phosphate levels were almost unchanged with age (r=-0.04, p=0.28) . In this multivariate model, total cholesterol and BMI were not significantly associated with phosphate levels and were not included.
Factors associated with the presence of atheroma plaque
Regarding subclinical atheromatosis assessed by carotid and femoral ultrasound, 69.4% of patients had atheroma plaque. Figure 2 provides a representation of the percentages of plaque by age, phosphate levels and sex, showing that atheromatous plaque risk clearly increases with age and with phosphate levels in all the intervals considered. In addition to this, Figure 2 also shows that for phosphate levels within the normal range (3.5 to 5 mg/dl) the risk of atheromatous plaque increased at younger ages for men than for women. As expected, classical cardiovascular risk factors were more prevalent in the group of patients with plaque, who were older (63.2±8.6 vs 50.8±13.6, p=<0.0001), had a higher prevalence of diabetes (81. Table 3 presents the results of the multivariate logistic regression model separately for each sex, categorizing age and phosphate levels as in the previous figure, showing that in men the classical cardiovascular risk factors (age, tobacco and diabetes) but also phosphate levels were significantly associated to plaque risk and, importantly, this effects were independent of glomerular filtration rate. Similar findings were found in women but the effect of the different ranges of phosphate was more prominent in the higher range.
Further adjustment for phosphate binder use was not significant and did not modify the coefficients nor the p values. Figure 3 describe the effect of phosphate levels on atheromatous plaque risk stratified by sex when adjusting by age, tobacco, diabetes, CRP and eGFR. A level of [3.5-5] mg/dl (within the normal range) of laboratory was associated in men to a higher risk of plaque when compared to the reference group with a phosphate level between [0-3.5] mg/dl and age between 18 and 45. However, in women a higher risk was only observed in the range between [5] [6] [7] [8] [9] [10] mg/dl above the normal range of laboratory. The effect of age and phosphate levels was also significant when considered as continuous variables in the multivariate models (results not shown) for both sexes.
DISCUSSION
In our study we found that in community-living individuals with a range of kidney function from moderate to severe CKD, higher phosphate levels are significantly associated with a higher risk for atherosclerosis. This association is different according to sex, so that phosphate levels within the normal range are associated with atheromatosis only in men.
In this study we have used the presence of plaque detected by ultrasound as an indicator of atheromatosis. Prior reports have demonstrated that carotid plaque and cIMT are highly correlated, and that each of them independently predicts cardiovascular events in non-CKD cohorts [25] . Furthermore, the presence of plaque seems to have an additive role to that of cIMT in estimating cardiovascular risk in the general population [26] . Similarly, studies in patients with CKD have been unable to find a difference between coronary artery calcification, carotid plaque, and cIMT in the ability to predict self-reported prevalent CVD [27] . Thus, the presence of plaque seems to be an effective surrogate marker for predicting cardiovascular events.
We have found that serum phosphate levels are associated with age, sex, the presence of diabetes and hypertension, the eGFR and levels of PTH and cholesterol. Interestingly, a strong interaction between sex and age was observed. Thus, as depicted in figure 1 , serum phosphate levels declined with age almost linearly among men. In women under the age of 40-45 years, phosphate levels overlapped those in men and then were progressively higher.
This effect remained when adjusting for variables known to affect phosphate levels as glomerular filtration rate and PTH. In this regard, it has been proven that phosphorus homeostasis is different in men and women [28] . The underlying mechanisms are uncertain, but there is evidence pointing to an effect of sex hormones in phosphate regulation [29] . Indeed, menopause and estrogen use affect serum phosphate concentrations [30] .
As in the general population, traditional cardiovascular risk factors like smoking or diabetes remained associated with the presence of plaques. However phosphate levels were also related with the presence of subclinical atheromatous disease in our CKD population both, in men and women.
However, serum phosphate seemed to have an effect on the presence of atheromatous plaque which was different as far as sex is considered. Thus in men, we found that fasting serum phosphate levels within the normal range were strong predictors of the presence of atheromatous plaque in CKD stages 3 to 5, as it has been described in the general population [31] . However the increased risk in women is only observed with phosphate levels over the normal range. This finding is supported by recent evidence suggesting that the association between serum phosphate levels and subclinical and clinical CVD in the general population may be different according to sex. [32] Whether serum phosphate is only a biomarker or a risk factor, is a question that remains to be elucidated. Thus, high FGF23 levels have been reported to be more strongly associated with vascular disease and mortality than serum phosphate levels. Furthermore, they were better predictors of adverse events in patients with normal serum phosphate [33] . In our study we did not determine FGF23 levels but, in any case, data are consistent with the hypothesis that higher phosphate levels are independent risk factors for atheromatous disease in CKD patients in which the contribution of other possible confounding factors has been ruled out. Furthermore, they provide important insights to delineate pre-clinical studies to conclusively establish whether the observed increases in atheromatosis result from a direct effect of elevations in serum phosphate or through phosphate activation of another pro-atheromatous mechanism. In turn, the identification of the pro-atheromatous mechanism induced by serum phosphate should help identify novel target for therapeutic interventions in individuals refractory to reductions in serum phosphate.
Strengths of this study include the relatively large population encompassing nearly every region of the country. Therefore, local bias was avoided.
Furthermore the carotid ultrasound was performed by a unique team and analysed by one reader in a blinded fashion, avoiding the well-known interoperator bias.
However some limitations should be noted as the use of estimated GFR as opposed to direct measurement, the lack of a control group without CKD and the use of a surrogate marker instead of clinical outcome data. In addition, our study might suffer from a selection bias due to those patients who declined to participate in the study, but this bias could not be assessed given that this information was not reported by the hospitals participating in this multicentric study. Besides, we relied on a single determination of serum phosphorus that may not accurately reflect time-averaged concentrations. In this regard, an isolated fasting morning serum phosphate measurement may underestimate 24-hour exposure. Furthermore this study lacks measurements of 1,25 hydroxyvitamin D or FGF23, which may be important mediators or confounders of the relationship between serum phosphate and the presence of atheromatous plaques [34] [35] [36] . The wide age range could also be considered a limitation of the study. However, in order to obtain an adequate sample size, the age range had to be widened. Thus, we have included pre and postmenopausal women. The perimenopausal period, at least in the general population, has been associated to higher levels of serum phosphate [37] . As menopausal status has not been recorded, we could not determine if phosphate levels were higher in menopausal women. In addition, the fact that this is an ancillary study from the NEFRONA study adds some limitations in the sense that no cause and effect relationships can be assessed and, in addition confounding variables have been selected from the available ones in the protocol.
In summary age, diabetes, smoking history and phosphate levels are variables significantly associated to atherosclerosis in CKD patients not in dialysis.
Although phosphate levels within the normal range are associated to the presence of atheromatous plaque in men, this association is not found in women until they reach pathological levels. Due to this differential effect regarding sex, recommended serum phosphate levels could be different for male than for female CKD patients and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010; 11: 14. Odds-ratios to evaluate the risk of atheromatosis depending on the phosphorus level, estimated by means of a logistic regression model adjusted by age, tobacco, diabetes, CRP and glomerular filtration rate. Reference category (OR=1) defined by those patients with phosphorus level between 0 and 3.5 mg/dl and age between 18 and 45 years, for each sex group. Segments represent 95% confidence interval for ORs Multiple logistic regression models determined with a stepwise procedure, considering all potential predictors and several interactions. Only variables with a significant effect or showing a potentially confounding influence in the model were maintained. Odds ratio, 95% confidence interval, Z values, defined as the estimated coefficients standardized by their standard error (beta/se(beta)) and p-values are provided. Age reference interval: 18-45 years; phosphorus reference interval: 0-3.5 mg/dl; diabetes and tobacco (yes/no), eGFR and CRP as continuous variables. eGFR: estimated glomerular filtration rate. CRP: C reactive protein. 
